Moleculin Biotech, Inc. Company profile
About Moleculin Biotech Inc
Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the treatment of resistant cancers and viruses through the development of its drug candidates. The Company has three product pipelines: Annamycin, WP1066 and WP1122. Annamycin is developed for the treatment of relapsed or refractory acute myeloid leukemia (AML). WP1066 is a immune or transcription modulators capable of stimulating immune response to tumors by inhibiting the errant activity of Regulatory T-Cells (TRegs) while also inhibiting key oncogenic transcription factors, including p-STAT3, c-Myc and HIF-1α. WP1122 is a prodrug of 2-deoxy-D-glucose (2-DG), which provides an opportunity to cut off the fuel supply of tumors by taking advantage of their overdependence on glucose as compared with healthy cells.
Financial summary
BRIEF: For the nine months ended 30 September 2021, Moleculin Biotech Inc revenues was not reported. Net loss decreased 11% to $13.1M. Lower net loss reflects Gain from change in fair value of warran increase from $1.5M to $4.4M (income), Research and development balancing value decrease of 2% to $10.5M (expense), Interest Income, Net increase from $10K to $236K (income).
Latest shares articles
![](https://img.capital.com/imgs/articles/384x2000x0/1350x880_-HP-_Newsquawk-light_1.png)
![Lloyds share price forecast: An attractive dividend stock?](https://img.capital.com/imgs/articles/384x2000x0/Hero-image-bank_1.png)
![Exterior of Infosys headquarters](https://img.capital.com/imgs/articles/384x2000x0/shutterstock_2035197281_0_0.jpg)
![Tesla logo atop of a Tesla Dealership illuminated at night.](https://img.capital.com/imgs/articles/384x2000x0/shutterstock_1494516293_0.jpg)